The Experience with Biosimilars of Infliximab in Rheumatic Diseases

Valderilio Feijo Azevedo, Igor Age Kos, Leonardo Ariello

Open source

DOI: 10.2174/1381612824666171129192040
Published: 2018-02-15
Container: Current Pharmaceutical Design
Publisher: Bentham Science Publishers Ltd.
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2174/1381612824666171129192040,
  title = {The Experience with Biosimilars of Infliximab in Rheumatic Diseases},
  author = {Valderilio Feijo Azevedo and Igor Age Kos and Leonardo Ariello},
  year = {2018},
  journal = {Current Pharmaceutical Design},
  doi = {10.2174/1381612824666171129192040},
  url = {https://doi.org/10.2174/1381612824666171129192040}
}

RIS

TY  - JOUR
TI  - The Experience with Biosimilars of Infliximab in Rheumatic Diseases
AU  - Valderilio Feijo Azevedo
AU  - Igor Age Kos
AU  - Leonardo Ariello
PY  - 2018
JO  - Current Pharmaceutical Design
DO  - 10.2174/1381612824666171129192040
UR  - https://doi.org/10.2174/1381612824666171129192040
ER  -

APA

Azevedo, V. F., Kos, I. A., & Ariello, L. (2018). The Experience with Biosimilars of Infliximab in Rheumatic Diseases. Current Pharmaceutical Design. https://doi.org/10.2174/1381612824666171129192040

Source records

crossref · retrieved 2026-11-10T18:52:55.976Z